Provenge approval expected to rejuvenate cancer vaccine industry

MARKETWIRE:  The approval of Dendreon’s prostate cancer vaccine Provenge in April was a boon for a nascent cancer vaccine industry that had suffered several setbacks, and should lead to an influx of market opportunities and a surge in regulatory activity. READ MORE>

Read Full Post »

Prostate cancer drug Provenge finally starts earning money for its maker

WALL ST JOURNAL: New wonder drug for treating advanced prostate cancer, Provenge, is finally making money for its manufacturer, Dendreon Corp. READ MORE>

Since the $93,000 treatment was launched at the beginning of May, doctors have written 500 prescriptions for the treatment, the company disclosed.

Read Full Post »

Provenge extends prostate patients’ lives about four months – at a cost of $130,000

ABC NEWS: The new US wonder drug for treating advanced prostate cancer – Provenge – extends life about four months – at a cost of $NZ130,000 ($US93,000).

The makers say it took 15 years to develop, at a cost of $US1.2 billion. READ MORE> and MORE>

Read Full Post »

Alternative business website purports to reveal scandal behind rival to Provenge’s eventual success

PROSTABLOG NZ: When global mainstream media reported the recent (partial) success of Dendreon drug company getting FDA approval for its new immunotherapy prostate cancer drug, Provenge, they didn’t mention how makers of a now-discredited rival drug may have delayed its path to chemist shops.

An “alternative” market investors’ website called Market Rap.com has just published a story by a former Wall Street Journal journalist that purports to reveal a murky background to what might be called – if it’s all, even partly, true – one of America’s biggest drug scandals.

It involves the US prostate Cancer Foundation (no relation to NZ’s) and its ubiquitous chairman, Michael Milken, who featured recently on the Larry King Live special about prostate cancer.

If you’ve got lots of time, READ MORE>

Read Full Post »

US drug company that will produce Provenge is so far having a bad year

PUGET SOUND BUSINESS JOURNAL: The US drug company that is about to produce the world’s most promising immuno-therapy prostate cancer treatment – Provenge – has reported a second-quarter loss of $126.7 million. READ MORE>

Read Full Post »

PROSTATE FUTURE: New drug will be ready for baby boomers

JUNE 11: SEEKING ALPHA.COM: A groundbreaking new treatment for prostate cancer, Provenge, will likely receive US Food and Drug Administration approval and become widely available just as the first Baby Boomers reach 65 in 2010.  READ MORE>

Read Full Post »